- Home
- NYC vs DYAI Comparison
NYC vs DYAI Comparison
Compare NYC & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | DYAI |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 17.0M |
| IPO Year | 2014 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NYC | DYAI |
|---|---|---|
| Price | $5.64 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 21.1K | ★ 192.2K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,090,345.00 |
| Revenue This Year | $56.73 | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.61 | $0.34 |
| 52 Week High | $13.97 | $1.60 |
Technical Indicators
Market Signals| Indicator | NYC | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 23.21 |
| Support Level | $5.90 | N/A |
| Resistance Level | $8.89 | $0.90 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 43.01 | 21.86 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.